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Development of the palate comprises sequential stages of growth, elevation, and fusion
of the palatal shelves. The mesenchymal component of palates plays a major role in
early phases of palatogenesis, such as growth and elevation. Failure in these steps may
result in cleft palate, the second most common birth defect in the world. These early
stages of palatogenesis require precise and chronological orchestration of key physiologi-
cal processes, such as growth, proliferation, differentiation, migration, and apoptosis.There
iscompellingevidenceforthevitalroleofTGFβ-mediatedregulationofpalatedevelopment.
We hypothesized that the isoforms of TGFβ regulate different cellular biofunctions of the
palatal mesenchyme to various extents. Human embryonic palatal mesenchyme (HEPM)
cells were treated withTGFβ1, β2, and β3 for microarray-based gene expression studies in
order to identify the roles ofTGFβ in the transcriptome of the palatal mesenchyme. Follow-
ing normalization and modeling of 28,869 human genes, 566 transcripts were detected as
differentially expressed inTGFβ-treated HEPM cells. Out of these altered transcripts, 234
of them were clustered in cellular biofunctions, including growth and proliferation, devel-
opment, morphology, movement, cell cycle, and apoptosis. Biological interpretation and
network analysis of the genes active in cellular biofunctions were performed using IPA.
Among the differentially expressed genes, 11 of them are known to be crucial for palatoge-
nesis (EDN1, INHBA, LHX8, PDGFC, PIGA, RUNX1, SNAI1, SMAD3,TGFβ1,TGFβ2, and
TGFβR1).These genes were used for a merged interaction network with cellular behaviors.
Overall, we have determined that more than 2% of human transcripts were differentially
expressed in response to TGFβ treatment in HEPM cells. Our results suggest that both
TGFβ1 and TGFβ2 orchestrate major cellular biofunctions within the palatal mesenchyme
in vitro by regulating expression of 234 genes.
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INTRODUCTION
Cleft lip and/or palate is one of the most prevalent birth defects
worldwide (1 in 800 live births; Schutte and Murray, 1999; Spritz,
2001),andiscausedbyfailuresinpalatedevelopment.Theforma-
tionof acontinuouspalateisacomplexprocesscomposedof mul-
tiple steps, including palatal shelf growth, elevation, attachment,
and fusion. Palatogenesis in the human spans from approximately
gestationalday48to59andtheoutgrowthof thesecondarypalate
can generally be detected around day 49. During day 54–55, the
palatine processes rapidly elevate, assuming a horizontal position
which allows them to grow toward each other, attach, and fuse
(Wyszynski,2002).Ingeneral,withslightvariationamongstrains,
the stages of palatogenesis in mice [12.5–16.5days post coitum
(dpc)] are extremely similar and comparable to that of humans;
therefore, mice have been used as a model to study human palate
development (Ferguson, 1988). The failure of palatal shelves to
Abbreviations: FC, fold change; HEPM, human embryonic palatal mesenchyme;
IKB, ingenuity knowledge base; IPA, ingenuity pathway analysis; MEE, medial edge
epithelium; TGFβ, transforming growth factor β.
grow and adhere after elevation is the most common type of cleft
palate defect documented in murine models (Chai and Maxson,
2006). The palatal cellular components originate from the cra-
nial neural crest (CNC)-derived palatal mesenchyme, concealed
with a veneer of pharyngeal ectoderm-derived epithelium (Ito
et al., 2003; Nakajima et al., 2010). A precise and time-sensitive
regulation of various mesenchymal biofunctions, such as cellu-
lar movement, cell death (apoptosis), cell morphology, cell cycle
progression, development, and growth and proliferation, is fun-
damental for the proper development of the palate. These cellular
functions are coordinated by numerous genes encoding a range
of growth factors, signaling mediators, transcriptional factors,
cytokines,and extracellular matrix proteins (Richman and Tickle,
1989; Greene and Pisano, 2004, 2005). Therefore it is immensely
important to explore the genes and the molecules that regulate
the plethora of these biofunctions to understand cellular behavior
during palatogenesis.
The TGFβ family consists of more than 30 ligand proteins,
including activins, BMP, and TGFβ cytokines, regulating a wide
variety of biological processes such as cellular development,
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morphology, movement, growth and proliferation, survival,
mitotic regulation, apoptosis, and epithelial–mesenchymal tran-
sition (EMT). Although the three isoforms of TGFβ (β1, β2, and
β3) are highly conserved between species (Rotzer et al., 2001)
and share 71–76% sequence identity, these ligands have isoform-
speciﬁc activities that cannot be compensated by other family
members (Iwata et al., 2011). Based on knockout mouse models,
TGFβ isoforms have been found to be essential for normal mor-
phogenesisof thepalate(IordanskaiaandNawshad,2011).TGFβ1
null mice are embryonically lethal and die before 11dpc (Brunet
et al.,1995),so its role in palate development cannot be evaluated.
TGFβ2 knockout mice,which are also embryonic lethal at 18dpc,
have defects in their mandible and maxilla, with 23% of cases
resulting in cleft palate (Sanford et al., 1997); whereas all TGFβ3
nullmicedevelopcleftpalate(Kaartinenetal.,1995;Proetzeletal.,
1995) and die within 24h after birth. Furthermore, TGFβ muta-
tions and expression patterns have been shown to be associated
with the occurrence of cleft lip and/or palate (Stoll et al., 2004).
Mutations in TGFβ1 and TGFβ3,aswellastheir variants,are asso-
ciatedwithcleftpalateinhumans(Lidraletal.,1998;Mitchelletal.,
2001; Kim et al., 2003; Vieira et al., 2003; Rullo et al., 2006; Guo
et al., 2010; Salahshourifar et al., 2011). Moreover, in vitro stud-
ies of human tissues showed that TGFβ1 and β3 are differently
expressed and correlated with the cleft lip and/or palate pheno-
type (Bodo et al., 1999). Overall, these ﬁndings underscore the
crucial function of TGFβ isoforms in the optimal regulation and
completion of palate development.
The TGFβ isoforms are expressed in the early stages of mouse
palate development (Fitzpatrick et al., 1990; Pelton et al., 1990;
Gehris et al.,1991; Gehris and Greene,1992). During the sequen-
tialstepsofpalatogenesis,TGFβ1isexpressedbothintheepithelial
and mesenchymal components of the palatal shelves (Fitzpatrick
etal.,1990;Peltonetal.,1990).TGFβ2ispredominantlyexpressed
in the mesenchymal cells, particularly immediately adjacent to
the epithelium, with few epithelial cells also expressing TGFβ2
transcripts (Fitzpatrick et al., 1990; Pelton et al., 1990; Gehris
and Greene, 1992). Intense and distinct localization of TGFβ3
has been detected in the medial edge epithelium (MEE) of the
palate (Fitzpatrick et al., 1990; Pelton et al., 1990). In our lab, we
havedemonstratedthatTGFβ3isalsoexpressedinthepalatalmes-
enchyme,albeitatalowerlevelcomparedtothepalatalepithelium
(Unpublished data). It has also been shown that each TGFβ lig-
and can signal via different receptor complexes and downstream
signaling molecules resulting in divergent cellular functions and
behavior(AbbottandPratt,1988;Iwataetal.,2011).Thereforethe
isoformsof TGFβmaybehaveuniquelyinthepalatalmesenchyme
compared to the palatal epithelium.
In this study, we investigated the crucial roles of TGFβ1, β2,
and β3 on the regulation of palatal mesenchyme transcriptome
and various cellular biofunctions, such as growth and prolifera-
tion,development,cellmorphology,movement,cellcycle,andcell
death. Using human embryonic palatal mesenchymal (HEPM)
cells and bioinformatics tools, we analyzed how these isoforms
regulate differential expression of transcripts and gene interac-
tion networks within the palatal mesenchyme. Using microarray
genechips, we found that expression of only 566 genes, which
corresponds to >2% of the overall human transcriptome, were
differentially expressed in TGFβ-treated HEPM cells with statisti-
cal signiﬁcance; including candidate genes recognized as inducers
of cleft palate either in human or mouse (EDN1, INHBA, LHX8,
PDGFC, PIGA, RUNX1, SNAI1, SMAD3, TGFβ1, TGFβ2, and
TGFβR1). We also found that exogenous TGFβ can regulate dif-
ferent molecules of the canonical TGFβ signaling pathway. Our
results suggest that both TGFβ1 and TGFβ2, in concordance, reg-
ulate expression of 234 genes that govern cellular biofunctions
which are crucial for the complete formation of the palate.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENT
The HEPM cell line (CRL 1486) was obtained from the Ameri-
can Type Culture Collection (ATCC; Rockville, MD, USA) from
a single human abortus at the time of palatal shelf elevation, but
prior to epithelial contact. HEPM cells represent the undifferenti-
ated ﬁbroblast-like cells from embryonic palatal shelves. The cells
were cultured at 37˚C with 5% CO2. The culture medium con-
sisted of DMEM (Mediatech, Manassas, VA, USA) supplemented
with 10% (v:v) fetal bovine serum (FBS) and 1% (v:v) penicillin
streptomycin.ForthemicroarrayandqPCRstudies,following24h
serum starvation, HEPM cells were treated either with 0.5% FBS
(Control) or with recombinant TGFβ (R&D Systems, Minneapo-
lis, MN, USA) at 10ng/ml TGFβ1, TGFβ2, or TGFβ3 for 24h in
triplicate and harvested for RNA extraction.
RNA EXTRACTION
Total RNA from the TGFβ-treated HEPM cells was extracted
using the RNeasy spin column RNA puriﬁcation kit (Qiagen, CA,
USA) according to the manufacturer’s instructions. RNA yield
and integrity were initially evaluated using a NanoDrop 2000c
spectrophotometer (NanoDrop, Wilmington, DE, USA). Sam-
ples with a concentration above 40ng/ml, OD260:280 of 1.8–2.0,
and OD260:230 above 1.8 were retained. Samples intended for
microarray analysis were further evaluated using the Agilent 2100
Bioanalyzer and RNA 6000 Pico kit (Agilent, Santa Clara, CA,
USA) according to the manufacturer’s instructions. Samples with
electropherograms exhibiting sharp 18S and 28S rRNA peaks and
no evidence of degradation were retained.
MICROARRAY PROCESSING
RNA samples from each treatment group of triplicates (Total:12)
wereproﬁledusingtheAffymetrixGeneChip®HumanGene1.0ST
Array(AffymetrixInc.,SantaClara,CA,USA)representing28,869
genes.Inthischip,eachofthegeneswasrepresentedonthearrayby
approximately 26 probes spread across the full length of the gene,
providing a more complete and accurate interpretation of gene
expression than 3  based expression array designs (Pradervand
et al., 2008). The microarray procedure was performed accord-
ing to the standard Affymetrix gene chip analysis protocol at the
UNMCMicroarrayCore.Threehundrednanogramsof totalRNA
was reverse transcribed and converted to double stranded cDNA
usingtheAmbionWTExpressionkit(Ambion,Austin,TX,USA).
The samples were subsequently subjected to fragmentation and
biotin end-labeling using the Affymetrix WT Labeling Kit and
hybridized per the manufacturers suggestions to the Affymetrix
Human Gene ST 1.0 arrays. The wash, stain, and scan proce-
dures were carried out on the Affymetrix Hybridization Oven, FS
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450 wash station, and the 7000G scanner per the manufacturer’s
recommendations (Affymetrix, Santa Clara, CA, USA).
qPCR
Synthesisof cDNApriortoqPCRwasperformedusingtheSuper-
Script®III First Strand SuperMix (Invitrogen,Carlsbad,CA,USA)
with5μginputtotalRNAper25μlreactionaccordingtotheman-
ufacturer’sinstructions.Negativecontrolsampleswereperformed
in parallel by omitting reverse transcriptase. The sequences of
primersforgenesofinterest(Table A1 inAppendix)weredesigned
using the PrimeTime qPCR Assay [Integrated DNA Technologies
(IDT), Iowa City, IA, USA) and synthesized by Euroﬁns MWG
Operon (Huntsville, AL, USA). All qPCR experiments were per-
formedusingcDNAsynthesizedfromthesamebatchandstarting
amountoftotalRNA.NegativecontrolscontainingnocDNAtem-
plate were included for each gene within each qPCR run. To avoid
variation in ampliﬁcation conditions across runs, reactions for
all experimental conditions (i.e., all untreated and TGFβ-treated
HEPM cells) for each gene of interest were performed as tripli-
cates in the same 96-well plate. Cycling conditions were designed
according to the RealMasterMix SYBR ROX handbook (5 PRIME,
Gaithersburg, MD, USA) as initial activation at 95˚C for 10min;
40 cycles of 95˚C for 15s, 60˚C for 1min. Ampliﬁcation speci-
ﬁcity for each gene was conﬁrmed by a single distinct melting
curve. Relative quantiﬁcation of gene expression was determined
by normalization of the samples with the internal reference gene,
GAPDH. Data from the triplicates was evaluated and analyzed for
signiﬁcance by the pair-wise ﬁxed reallocation randomization test
using the REST 2009 software (Pfafﬂ et al., 2002). A p-value of
≤0.05 was considered signiﬁcant.
DATA ANALYSIS: NORMALIZATION AND DIFFERENTIAL GENE
EXPRESSION
ScannedarrayimageswereanalyzedbydChipapplyingasmooth-
ing spline normalization method prior to obtaining model-based
geneexpressionindices,a.k.a.signalvalues.Therewerenooutliers
identiﬁed by dChip, so all samples were carried on for subse-
quentanalysis.Whencomparingtwogroupsofsamplestoidentify
enriched genes in a given group, we used the lower conﬁdence
bound (LCB) of the fold change (FC) between the two groups as
the cut-off criteria. If 90% LCB of FC between the two groups
was above 1.2, the corresponding gene was considered to be dif-
ferentially expressed. LCB is a stringent estimate of the FC and
has been shown to be the better ranking statistic (Li and Wong,
2001). By use of LCB,we can be 90% conﬁdent that the actual FC
is some value above the reported LCB. Researchers demonstrated
that (Ramalho-Santos et al.,2002) selecting genes that have a LCB
above 1.2 most likely corresponds to genes with an“actual”FC of
at least three in gene expression. For all genes scored, the FC was
calculated by dividing the experiment value by the control value.
If this number was less than one,the (negative) reciprocal is listed
(e.g.,0.75oradropof 25%fromcontrolisreportedas−1.25FC).
ThereportedFCsaretheaverageof theindependentexperiments.
All of the signiﬁcantly changed genes (FC >1.2-fold down or up)
were selected for the biofunctional analysis. p-Values less than
0.05 indicated a statistically signiﬁcant, non-random association.
The complete list of genes passing dChip’s statistical ﬁlter for each
treatment with their respective FCs and p-values was deposited to
the gene expression omnibus (GEO) of NCBI (Accession num-
ber: TBD). To compare the results of our multiple microarray
experiments,wedrewVenndiagramswhichdepictedtherelations
among the TGFβ treatment groups as intersections or uniqueness
using the GeneVenn (Pirooznia et al.,2007).
CLUSTERING AND FUNCTIONAL ANALYSIS
Clustering of samples and genes was performed using the
unweighted pair group method with arithmetic-mean (UPGMA),
a hierarchical clustering technique used to construct a similar-
ity tree, and principal components analysis (PCA; Sneath, 1973;
Handl et al., 2005). Heatmaps with dendrograms are constructed
using Bioconductor of R statistical software (Gentleman et al.,
2004;ReimersandCarey,2006).Samplesandgeneswereclustered
using the normalized and modeled expression values obtained by
dChip analysis. The expression data matrix was row-normalized
for each gene prior to the application of average linkage clus-
tering and the Pearson’s correlation was used as the distance
measure. In the heatmaps, each column corresponds to the aver-
aged expression proﬁle of a treatment in triplicate, and each
row corresponds to an mRNA. The upper portion (green-to-
red) represents downregulated transcripts and the lower portion
(red-to-green) represents upregulated transcripts. The increasing
intensities of red signify a higher expression in the given sample
of a speciﬁc mRNA, whereas the increasing intensities of green
indicate a lower expression of mRNA and black indicates mean
level expression. Functional analysis was comprised of ﬁnding
gene ontology (GO) categories in the gene clusters of interest
that warrant further investigation. GO annotations are used for
the biological interpretation of detected clusters (Ashburner et al.,
2000).
BIOLOGICAL INTERPRETATION AND PATHWAY ANALYSIS
The effects of TGFβ on cellular functions of HEPM cells were
examined in the context of differentially expressed human genes
using the ingenuity pathway analysis (IPA; Ingenuity Systems,
CA, USA) a web-delivered application used to discover, visual-
ize, and explore relevant networks. Following statistical analysis
and ﬁltering of the microarray data using dChip, Affymetrix
probe identiﬁers, and fold-values of each treatment group were
uploaded to IPA as a dataset. Each identiﬁer was mapped to its
correspondinggeneobjectintheingenuityknowledgebase(IKB).
Interactionswerethenqueriedbetweenthesedatasetsandallother
geneobjectsstoredwithinIPAtogenerateasetofdirectinteraction
networksthatwereoverlapped.Thesigniﬁcantgeneswerecatego-
rized, compared to functional categories in the IPA database, and
ranked according to their p-values. p-Values less than 0.05 indi-
cate a statistically signiﬁcant, non-random association between a
set of signiﬁcant genes and a set of all genes related to a given
function in the IKB (Mori et al., 2009). Through the assessment
of differentially expressed genes, cellular processes that are most
signiﬁcantlyalteredinourdatasetwere:cellulargrowthandprolif-
eration, development, morphology,movement,cell cycle,and cell
death. Using these IPA analyses,molecules within the cellular bio-
functioncategorieswereﬁlteredandimportedtoExcel(Microsoft,
Seattle,WA, USA) for further graphical analysis of the networks.
www.frontiersin.org April 2012 | Volume 3 | Article 85 | 3Zhu et al. TGFβ-treated HEPM transcriptome
RESULTS
TGFβ REGULATES DIFFERENTIAL EXPRESSION OF MORE THAN 2% OF
THE PALATAL MESENCHYME TRANSCRIPTOME
We performed gene expression proﬁling on the Affymetrix
GeneChip®Human Gene 1.0 ST Array representing 28,869 genes.
We explored the alterations in gene expression in HEPM cells
extracted from human embryonic palatal shelves in response to
10ng/ml TGFβ1,TGFβ2,and TGFβ3 for 24h. Statistically signiﬁ-
cantalteredgeneswereﬁlteredusingdChipthroughnormalization
andmodelinganalysis.Outof 28,869genesrepresentedwithinthe
GeneChip®, 301 genes demonstrated upregulated and 200 genes
demonstrated downregulated expression in response to TGFβ1
treatment.Similarly,190geneswereupregulatedand77geneswere
downregulatedinresponsetoTGFβ2treatment.Interestingly,only
four genes demonstrated increased and four genes demonstrated
decreased expression patterns in response to TGFβ3 treatment.
The numbers of differentially expressed genes,indicating individ-
ual and overlapping aggregations of TGFβ isoforms, are depicted
in aVenn diagram (Figure 1).
The genes (n =27) displaying the most signiﬁcant changes in
expression patterns in response to TGFβ1 and TGFβ2 stimula-
tion with their FCs and p-values are shown in Table 2. According
to dChip normalization and modeling, the level of differential
gene expression by TGFβ3 was detected to be statistically non-
signiﬁcant;thereforeTGFβ3hasbeenexcludedfromtheFCanaly-
sis.Transcripts,whichweredifferentiallyexpressedbothbyTGFβ1
and TGFβ2, are highlighted in the table (Table 2). Graphical rep-
resentation of FC values detected by microarray analysis is shown
in Figure 2A. In order to validate the gene expression proﬁling
results of these most signiﬁcantly up- and downregulated tran-
scripts,expression levels of 27 genes were quantiﬁed by qPCR and
compared to the levels determined by microarray (Figure 2B).
Expression proﬁles of all 27 genes tested were found to be in
agreement between the two analytical assay results. We identiﬁed
a strong correlation of gene expression pattern between microar-
ray and qPCR data in terms of up- and downregulation, but not
relative level of expression.
Furthermore, direct or indirect relations of these 27 genes
with TGFβ signaling were detected using IPA. Among the signiﬁ-
cantly upregulated transcripts, we detected that ANKRD1, EDN1,
IGFBP3, ITGB3, NOX4, NEDD9, PMEPA1, TNFAIP6, and VDR
were directly related with TGFβ; while AMIGO2 and MSC were
indirectly associated with TGFβ via other molecules (Figure 3A).
Within the signiﬁcantly downregulated gene group HGF, NR4A2,
SMAD3,andTGFBR3presentedadirectrelationwithTGFβ;while
transcripts of TBC1D8, GDF5, IFIT2, and OAS1 presented an
indirect association with TGFβ via other molecules (Figure 3B).
We focused on the differential expression of genes involved in
cellularbiofunctionswithacriterionofFC>1.2usingtheIPAsoft-
ware. While several genes overlapped based on cellular functions,
we were able to cluster them according to their GO annotations
as:cellcycle,celldeath,cellmorphology,growthandproliferation,
development, and movement (Table 1). The individual heatmaps
were generated according to hierarchal clustering of genes which
are involved in the cellular processes (Figure4). According to IPA
analysis, there were 66 differentially expressed genes detected to
havearoleincellularmovement;48wereupregulated,and18were
FIGURE 1 |Venn diagrams. Multiple microarray experiments were
designed to detect differential expression of transcripts withTGFβ
treatment and were compared using Venn diagrams. List of differentially
expressed genes with their accession IDs were uploaded to GeneVenn,
query was run, and the detected numbers and gene lists were exported to
MS Excel. Graphical ﬁgure is illustrated using the Adobe Photoshop (Adobe
Inc, CA, USA). Relations among the list of altered genes withinTGFβ
treatment groups are depicted as intersections or uniqueness. A signiﬁcant
overlap of differentially expressed genes was observed between theTGFβ1
andTGFβ2 treatment groups both in the upregulated (A) or downregulated
(B) gene lists.
downregulated in response to TGFβ treatment. Eighty genes were
found to play a role in apoptosis (cell death); 55 demonstrated
increased expression, while 25 displayed lower expression levels).
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Fifty genes function in cell morphology; 12 were downregulated
and 38 were upregulated. Cellular development included 91 genes,
among which 53 were upregulated and 38 were downregulated.
FIGURE 2 | Expression levels of the most signiﬁcantly up- and
downregulated genes based on microarray and qPCR analyses.The
graphical representation of genes (n=27) displaying the most signiﬁcant
changes in expression patterns in response toTGFβ stimulation with their
FC values based on microarray analyses were shown (A). OnlyTGFβ1 and
TGFβ2 treatments were represented in (A) due to their statistically
signiﬁcant p-values detected by dChip. (B,C) Gene expression proﬁles of all
27 genes were independently validated using qPCR and data was analyzed
using REST 2009 (Pfafﬂ et al., 2002). Expression variation for each gene
was visualized in a whisker-box plot.Transcripts were sorted alphabetically.
TheCellcycle GOwasrepresentedby37genes;20wereupregulated
and 17 were downregulated. The GO cluster containing the high-
est number of differentially expressed genes (n =93) compared
to other cellular biofunction clusters was the cellular growth and
proliferation GO,including 57 upregulated and 36 downregulated
transcripts.
A representation of the network-based interactions of the dif-
ferentially expressed genes, according to their cellular biofunc-
tions, and their molecule type, is shown in Figure 5.D u et o
the high number of genes in each biofunction, we preferred
the genes with an FC >2.0 for network interactions. In the cell
cycle network, only three genes (SMAD3, let-7, and EPGN)w e r e
downregulated, and seven genes (mir-199, IGFBP3, SKIL, NOX4,
IVNS1ABP,EDN1,andNEDD9)wereupregulated.Withinthecel-
lular movement network there were 4 signiﬁcantly downregulated
genes (SMAD3, SERPINB2, GDF5, and NPTX1) and 15 upregu-
lated genes (ADAM19, VDR, VLDLR, NUAK1, NEDD9, LRRC15,
mir-199, IGFBP3, EDN1, MAP2, ADAM12, LTBP2, IVNS1ABP,
NOX4, and ITGB3) in response to TGFβ treatment. In the net-
work of cellular growth and proliferation,w ed e t e c t e d8g e n e s
(TRA2A, EPGN, GDF5, SERPINB2, SMAD3, let-7, GPAM, and
mir-218) which were downregulated, while 17 genes (KCNH1,
ITGB3, PMEPA1, NOX4, IVNS1ABP, VLDLR, IGFBP3, ADAM12,
EDN1,AK4,VDR,ANKRD1,TGFβI,NEDD9,SKIL,TNFAIP6,and
SPOCK1) were upregulated. Downregulated genes belonging to
thecellmorphology GOnetworkincludeNPTX1andSMAD3;and
upregulated genes (n =11) include LTBP2, VDR, ASPN, TGFβI,
IGFBP3, EDN1, MAP2, VLDLR, NEDD9, NOX4, and ITGB3.I n
thecellulardevelopment network,6genes(mir-218,TRA2A,GDF5,
SERPINB2, SMAD3, and let-7) were downregulated and 12 genes
(EDN1, PMEPA1, SKIL,VDR,ASPN, IVNS1ABP,TGFβI,VLDLR,
NOX4,IGFBP3,ITGB3,andKCHN1)wereupregulated.Withinthe
cell death (apoptosis) GO network, 5 genes (NPTX1, GDF5, SER-
PINB2, SMAD3, and GPAM) were downregulated and 14 genes
(NUAK1,SKIL,VDR,AMIGO2,ANKRD1,TGFβI,ADAM12,mir-
199, IVNS1ABP, IGFBP3, NEDD9, NOX4, EDN1, PMEPA1, and
ITGB3) were upregulated.
EXPRESSION LEVELS OF OROFACIAL DEVELOPMENT GENES ARE ALSO
AFFECTED BY TGFβ TREATMENT
A table of genes vital to the morphogenesis of orofacial develop-
ment was constructed based on the most recent literature review
(Table A2 in Appendix; Wilkie and Morriss-Kay, 2001; Lidral and
Moreno,2005; Gritli-Linde,2007; Dixon et al.,2011). Genes from
the table of cellular biofunctions (Table 1)w e r em e r g e dw i t ht h e
Table A2 in Appendix to ﬁlter the differentially expressed genes
according to putative candidates for palatal deformities. Some of
the genes listed were identiﬁed as being important for palatogene-
sis in mouse,but not directly associated with human cases of cleft
palate and thus remain “putative” cleft palate genes in the latter,
as labeled with asterisk (∗)i nt h eTable A2 in Appendix. Over-
lapping genes (n =11) were presented in Table 2 with their FC
and p-values. Among these genes,EDN1,INHBA,TGFβ1,TGFβ2,
RUNX1,LHX8,SNAI1,PDGFC,andPIGAwereupregulated;while
only SMAD3 was downregulated in response to TGFβtreatment.
Intriguingly, TGFβR1 was upregulated with TGFβ1 treatment
and downregulated with TGFβ2 treatment; which correlates with
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FIGURE 3 | Direct and indirect relations of most differentially
expressed genes withTGFβ. Affymetrix probe identiﬁers and FC
values of signiﬁcantly altered transcripts (n=27) were uploaded to IPA
and each identiﬁer was mapped to its corresponding gene object in the
IKB. Interactions were then queried between these gene objects and
all other gene objects stored within IPA to generate a set of direct
interaction networks that were merged. Networks with the highest
number of molecules were selected, overlaid withTGFβ molecules,
and organized using Path Designer of IPA. Upregulated transcripts
were highlighted with orange (A); and downregulated transcripts were
highlighted with green (B).Types of molecules were annotated in the
legend in the box.
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Table 1 | Differentially expressed molecules clustered into GO of cellular biofunctions.
Function Molecules
Cell cycle TGFBR1, PCGF2, SGK1, SMAD3, S100A4, MKI67 , DDB2, LIMK1, CAMK2D, BOP1/LOC727967 , TGFB1, HIPK2, POLK,
NEDD4L, ALDH3A1, PDGFRB, TP53, STAT6, DLG1, AMACR, NOX4, mir-199, SNAI1, STK38L, ANLN, JUNB, INHBA,
KAT2B, IGF2, IRS1, BHLHE40, MBD4, SIK1, KIF11, RUNX1, SULF1,TPM1, GADD45B, USP2, SEPT9, FAS, EIF4EBP1,
KSR1, CDC25B, EDN1, ASPM, CCDC99, MPHOSPH6, HGF , FOXO3,TOP2A, NEK7 , RPS6KA2, NUSAP1,TNC, PPARD,
MGMT,GNAI1,SMAD7 ,XBP1,GRB10,IVNS1ABP ,CENPI,CSF1,KIF20B,CAT,KLF5,ZEB2,SKIL,NCOR2,mir-27 ,NEDD9,
IRAK4
Cell death CTGF , TGFBR1, PCGF2, APH1B, SGK1, TGFBR3, DDB2, NPTX1, BNIP3, SGPL1, GDF5, PRDM1, SERPINE1, HIPK2,
ALDH3A1, MVP , ITGB5, PDGFRB,TP53, STAT6, mir-199, NOVA1, NDRG1, DDIT4, FOXP1, SLC2A1, SNAI1, JUNB, CDH2,
CD9, IRS1, BHLHE40, MBD4, SFRP1, FLNB, TCF4, GADD45B, ZFP36, IL17RD, PTPN13, HYOU1, TAOK3, EIF4EBP1,
KSR1, EFNA5, RYBP , TOP2A, PARP4, RPS6KA2, TLR3, VDR, FAP , OAS1, UCP2, TNC, TGFBI, MGMT, XBP1, FAIM2,
OBFC2A, MMP10, TRIB3, P2RX7 , PTGES, SEMA3A, KLF7 , CSF1, BMF , ZEB2, CTH, NCOR2, NEDD9, SGCD, PTGR1,
AMIGO2,IRAK4,CHRNA1,EPHB2,SMAD3,DPYSL4,UNC5B,S100A4,RBP1,CAMK2D,TGFB1,POLK,SMAD1,RAI14,
ITGB3BP , PTPRE, NOX4, PDE4B, CDCA2, INHBA,TMEM57 , ITPK1, KAT2B, ANKRD1, IGF2, NUAK1, ALDH3B1, JAG1,
SIRPA, PMEPA1, TNFAIP8, RUNX1, KDM3A, SULF1, TPM1, DPYSL3, KLF10, LIMS1, USP2, FAS, PRDX6, CDC25B,
SYVN1, EDN1, HGF , FOXO3, NEK7 , EYA4, ADRB2, SCN2A, PPARD, BGN, SMAD7 , IKBKE, DLX2, ITGB3, GRB10,TSHZ3,
IVNS1ABP , EBF1, B4GALT1, LAMA4, KLF5, CAT, SH3RF1, SKIL, ATP2B4
Cellular growth and proliferation TGFBR1, CTGF , PCGF2, TGFBR3, DDB2, MKI67 , BNIP3, SGPL1, MFAP2, GDF5, BOP1/LOC727967 , AFAP1, OSMR,
PRDM1,HIPK2,SERPINE1,SPOCK1,ALDH3A1,ITGB5,MVP ,PDGFRB,TP53,STAT6,AMACR,FOXP1,SLC2A1,FBLN5,
NDRG1, ANLN, GRK5, JUNB, VLDLR, CDH2, CD9, IRS1, GLUL, SFRP1,TRIM22,TNFAIP6,TCF4, SLC4A2, GADD45B,
ZFP36, PTPN13, BMPR2, SEPT9, EIF4EBP1, KSR1, PTPRJ,TLR3,VDR, IRX3, GLMN,TNC,TGFBI, MGMT, XBP1,TOB1,
PDLIM2, P2RX7 , SLC29A1, SEMA3A, PTGES, NOV, CSF1, KIF20B, BMF ,TBC1D8, ZEB2, CTH, NCOR2, NEDD9, IRAK4,
CHRNA1, EPHB2, SMAD3, UNC5B, S100A4, mir-221, PBX1, RBP1, TSC22D3, LIMK1, STARD10, CAMK2D, TGFB1,
RORA, ITGA11, SLC7A5, SMAD1, PTX3, DLG1, PFKFB3, PTPRE, NOX4, STK38L, INHBA, KAT2B, ANKRD1, IGF2,
MAPRE2, JAG1, SIRPA, KIF11, PMEPA1, TNFAIP8, RUNX1, TPM1, KLF10, PDGFC, PLEKHO1, FAS, CDC25B, AEBP1,
EDN1,HGF ,FOXO3,ENPP2,ADRB2,PPARD,BGN,SMAD7 ,IKBKE,MSI2,EDF1,PIGA,AFF1,GRB10,ITGB3,IVNS1ABP ,
B4GALT1, LAMA4, KLF5, CAT, SKIL, C5orf13, SHMT2
Cell morphology EPHB2, ANK1, BNIP3, ITGA11,TGFB1, PRDM1, CDC42EP1, SERPINE1, NEDD4L, ITGB5,TP53, DLG1, NOX4, INHBA,
IGF2, CD9, IRS1, CDC42SE1, JAG1, SIRPA, TPM1, FLNB, SULF1, SLC4A2, LTBP2, FAS, KSR1, EDN1, EFNA5, HGF ,
FOXO3, VDR, ADRB2,TNC,TGFBI, PPARD, ADCY3, SMAD7 ,TOB1, P2RX7 , PVR, PIGA, EDF1, ITGB3, SEMA3A, CAP2,
CSF1, LAMA4, CAT, NEDD9
Cellular development GFBR1, CTGF , PCGF2, TGFBR3, DDB2, BNIP3, SGPL1, GDF5, OSMR, PRDM1, HIPK2, SERPINE1, ITGB5, PDGFRB,
TP53, AMACR, STAT6, FOXP1, FBLN5, NDRG1, SNAI1, JUNB, VLDLR, CDH2, CD9, IRS1, BHLHE40, GLUL, SFRP1,
FLNB, TCF4, MSC, SLC4A2, GADD45B, ZFP36, PTPN13, NID2, IL17RD, BMPR2, SEPT9, SMURF1, KSR1, EFNA5,
TOP2A, DAGLB,TLR3,VDR, IRX3, GLMN,TNC,TGFBI, NRP2, MGMT, XBP1,TOB1,TRIB3, P2RX7 , PVR, SEMA3A, NOV,
CAP2,CSF1,KIF20B,BMF ,ZEB2,LBH,NCOR2,IRAK4,EPHB2,SMAD3,UNC5B,mir-221,S100A4,PBX1,SYNE1,RBP1,
BPGM,TSC22D3, ANK1, LIMK1, RORA,TGFB1, ITGA11, LHX8, SMAD1, DLG1, NOX4, LMO4, INHBA, IFRD1, KAT2B,
IGF2, BHLHE41, CDC42SE1, JAG1, SIRPA, PMEPA1,TNFAIP8, RUNX1, KDM3A,TPM1, GLIS3, KLF10, FAS, PLEKHO1,
CDC25B, EDN1, ASPM, HGF , FOXO3, MKL2, PHGDH, LONP1, ADRB2, VEZF1, PPARD, BGN, SMAD7 , IKBKE, DLX2,
MSI2, EDF1, PIGA, GRB10, ITGB3, AFF1, IVNS1ABP , EBF1, B4GALT1, LAMA4, CAT, KLF5, SKIL, C5orf13
Cellular movement CTGF ,TGFBR1,TGFBR3, NPTX1, SGPL1, GDF5, SCHIP1, AFAP1, SERPINE1, HIPK2, ITGB5, PDGFRB,TP53, STAT6, mir-
199,FBLN5,SLC2A1,NDRG1,SEMA5A,SNAI1,ANLN,JUNB,VLDLR,CDH2,CD9,IRS1,SFRP1,FLNB,LTBP2,BMPR2,
SEPT9, PARP9, PTPRJ, PCDH10, EFNA5, PPAP2B, TOP2A, CHST10, VDR, TLR3, FAP , UCP2, TNC, NRP2, MMP10,
LRRC15, PDLIM2, PVR, P2RX7 , SEMA3A, PTGES, NOV, CSF1, KIF20B, ZEB2, ANXA3, NEDD9, IRAK4, EPHB2, SMAD3,
UNC5B, S100A4, LIMK1, TGFB1, NEDD4L, NOX4, STK38L, PDE4B, INHBA, IGF2, NUAK1, JAG1, SIRPA, COL7A1,
TNFAIP8, SULF1, TPM1, LIMS1, FAS, SP100, CDC25B, EDN1, HGF , FOXO3, ENPP2, ADRB2, NUSAP1, PPARD, BGN,
SMAD7 , GNAI1, DLX2, ITGB3, IVNS1ABP , EBF1, B4GALT1, CAT, KLF5, ASAP2, C5orf13, ATP2B4
isoform-speciﬁc receptor requirement in TGFβ signaling (Rojas
et al.,2009).
Ingenuity pathway analysis, a knowledge based program
to generate relevant and interacting biological networks, was
used to determine how the differentially expressed overlap-
ping genes might interact to facilitate cellular biofunctions. A
direct interaction network of the orofacial deformity suscepti-
bility genes, overlaid with clustered cellular biofunctions cru-
cial for development and maturation of the palatal mesenchyme
was generated and is presented in Figure 6. Finally, the local-
ization of differentially expressed genes within the canonical
TGFβ pathway was illustrated by using the IPA Path Designer in
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FIGURE 4 | Hierarchical clustering (heatmap) analysis of differentially
expressed transcripts. Altered genes were clustered based on cellular
biofunctions and heatmaps were constructed using Bioconductor.
Coexpressed groups of genes were illustrated with dendrograms and
progressively and distinctly up- or downregulated genes were ranked
accordingly. Each column corresponds to the expression proﬁle of a treatment
(eitherTGFβ or Control) in triplicate, and each row corresponds to a transcript.
The increasing intensities of red signify a higher expression in the given
sample of a speciﬁc mRNA, whereas the increasing intensities of green
indicate a lower expression of mRNA and black indicates mean level
expression.The list of genes for each particular function (A–F) was shown in
Table 1.
Figure 7. The overlapping genes were: TGFβ1, TGFβ2, INHBA
(activins/inhibins), BMPR2, SMAD7, SMURF1, SMAD 1/5/8,
SMAD2/3, VDR, and PAI-1; suggesting that not all of the TGFβ
pathway molecules are signiﬁcantly regulated by exogenous TGFβ
treatment. The list of genes regulated by differentially expressed
TGFβ signaling molecules and their level of altered expression
are represented at Table 3. The full list of these genes, including
non-signiﬁcantly altered, is provided in Table A4 in Appendix.
DISCUSSION
Following vertical positioning of the palatal shelves along both
sides of the tongue, each shelf elevates to a horizontal position
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FIGURE 5 | Network of cellular biofunctions and corresponding
transcripts. Networks were constructed with the IPA software using the
selected genes matching the criterion of FC >2.0 and involved in cellular
biofunctions. Several differentially regulated genes from the study were used
to construct a gene association map for predicting various cellular and
molecular events operating within the palatal mesenchyme (A–F).R e d
symbols specify upregulated expression of genes, whereas green symbols
indicate downregulated genes.The color darkness represents the FC intensity.
abovethetongue.Inordertoexplainthisreorientationandexten-
sionseveralhypotheseshavebeenproposed,including:mesenchy-
malproliferationandorganization(Jinetal.,2010),mesenchymal
andmuscularcontraction(Innes,1978),generationof hydrostatic
f o r c e sb yh y a l u r o n a n( Goudy et al., 2010), and epithelial reorga-
nization (Babiarz et al., 1979). Taken as a whole, cellular changes
within the palatal mesenchyme, which composes the majority of
the palatal shelves, governs the optimum growth and elevation of
the palatal shelves prior to adherence and fusion (Ito et al., 2003;
Iwata et al.,2010,2011). HEPM cells,which were extracted from a
singlehumanabortusatthetimeof palatalshelf elevation(Yoneda
and Pratt, 1981), have previously been used in several studies,
including: determining the mechanisms of cleft palate develop-
ment induced by various teratogens (Dhulipala et al.,2004,2011),
the role of various growth factors active in the regulation of palate
development(Takechietal.,2008),andtheteratogenicpotentialof
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Table 2 |The most signiﬁcantly altered genes within the palatal mesenchyme withTGFβ treatment.
TGF-β1 TGF-β2 TGF-β3
TOP-10 UPREGULATED GENES
Gene name FC p-Value Gene name FC p-Value Gene name FC p-Value
AMIGO2 22.89 4.88E-03 AMIGO2 19.66 1.30E-05 KIAA1654 1.56 2.18E-02
NOX4 13.87 2.28E-02 NOX4 11.12 2.72E-02 NTM 1.47 3.91E-02
TNFAIP6 9.36 1.02E-02 ANKRD1 10.33 2.38E-03 LAMA1 1.46 3.58E-02
DACT1 8.02 7 .88E-03 KCNH1 7 .76 2.14E-02 LRP11 1.41 3.78E-02
ANKRD1 6.52 4.48E-02 EDN1 6.48 1.65E-02
PMEPA1 5.69 1.56E-03 DACT1 6.47 2.54E-03 Common upregulated
MSC 5.55 2.01E-02 PMEPA1 5.55 2.23E-02
EDN1 5.23 1.44E-02 HAPLN1 4.89 1.37E-02
VDR 5.19 1.36E-03 VDR 4.75 6.66E-04
ITGB3 5.19 1.04E-02 NEDD9 4.54 4.67E-03
TOP-10 DOWNREGULATED GENES
GDF5 -4.08 2.07E-02 TBC1D8 -2.570 6.70E-03 GEN1 -1.40 2.75E-02
SECTM1 -3.33 2.44E-02 SECTM1 -2.540 4.37E-02 POLK -1.49 1.40E-02
NPTX1 -3.25 1.61E-02 SMAD3 -2.510 1.63E-02 FLVCR2 -1.52 4.42E-02
SMAD3 -3.24 1.09E-02 OAS1 -2.290 3.95E-02 CPA4 -1.70 1.40E-02
OAS1 -3.11 2.27E-02 ARHGAP28 -2.230 4.42E-02
TBC1D8 -3.06 4.50E-03 NPTX1 -2.220 2.59E-02 Common downregulated
TRERF1 -2.75 3.35E-03 VSIG1 -2.190 3.11E-02
VSIG1 -2.75 3.00E-02 HGF -2.150 9.75E-03
TGFBR3 -2.62 2.82E-03 NR4A2 -2.020 4.56E-02
CA12 -2.59 7 .71E-03 IFIT2 -1.970 3.39E-02
GENES SUSCEPTIBLE FOR CRANIOFACIAL DEFORMITIES
EDN1 5.23 1.44E-02 EDN1 6.48 1.65E-02
INHBA 2.54 7 .20E-03 INHBA 2.21 1.62E-02
LHX8 1.62 1.84E-02 LHX8 NS NS
PDGFC 2.21 6.21E-03 PDGFC 2.06 5.95E-03
PIGA 1.51 1.71E-02 PIGA NS NS
RUNX1 1.78 1.06E-03 RUNX1 1.68 1.39E-03
SMAD3 −3.24 1.09E-02 SMAD3 −2.51 1.63E-02
SNAI1 1.75 1.39E-02 SNAI1 1.63 4.50E-02
TGFβ1 1.91 3.26E-03 TGFβ1 1.59 2.29E-03
TGFβ2 NS NS TGFβ2 1.78 4.22E-02
TGFβR1 1.49 2.05E-02 TGFβR1 −1.81 7 .33E-03
NS, Non-signiﬁcant expression detected by dChip. Red (A): Genes upregulated in response to bothTGFβ1 andTGFβ2. Green (B): Genes downregulated in response
to bothTGFβ1 andTGFβ2.
environmental agents (Watanabe et al., 1990). Therefore, HEPM
cells serve as a physiologically relevant model to study differential
expressionproﬁlingofgeneswhichfunctioninpalatalgrowth,ele-
vation,and extension; which are all indispensable for mammalian
palatogenesis.
We analyzed the raw data of scanned GeneChip images using
dChip, which normalizes and models the signal values of tran-
scripts in order to accurately detect differential expression with
FC values.We set the p-value <0.05 as a cut-off criterion of statis-
tical signiﬁcance for all raw data analysis. Although the raw signal
values of hybridized transcripts, i.e., prior to statistical ﬁltering,
exhibited differential expression of more than 12,000 genes in all
TGFβ-treated samples (data not shown), TGFβ3 group could not
pass the more stringent statistical signiﬁcance threshold. There-
fore, only 8 genes were detected to be differentially expressed in
response to TGFβ3 treatment in HEPM cells (Table 1), while
expression of more than 500 genes was altered in TGFβ1 and
TGFβ2 group. Based on these criteria of microarray data analysis,
we concluded that TGFβ3 treatment did not result in signiﬁcant
changes in expression levels of transcriptome of HEPM cells.
There are a number of methods to compare the differential
expression of genes in different treatment group using multiple
microarray experiments. For several years, Venn diagrams have
been shown to be the most effective graphical analysis tool to
demonstrate similarities, differences and distinctions within gene
sets (Kestler et al., 2005; Pirooznia et al., 2007). In our study,
we used Venn diagrams to illustrate the number of altered genes
within the HEPM cells in response to TGFβ isoform treatments as
overlapping and individual gene numbers (Figure 1). The num-
berof genesdifferentiallyexpressedbyTGFβ2ismuchhigherthan
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FIGURE 6 | Merged interaction network of cleft palate susceptibility
genes and biofunctions. Affymetrix probe identiﬁers and fold-values
were uploaded to IPA and each identiﬁer was mapped to its
corresponding gene object in the IKB. Interactions were then queried
between these gene objects and all other gene objects stored within IPA
to generate a set of direct interaction networks that were merged.
Cellular functions that directly interact with differentially expressed
putative candidate genes for cleft palate in response toTGFβ treatment
of HEPM cells were included in the network.The 11 transcripts meeting
the 0.05 criteria of FDR in response toTGFβ treatment were analyzed for
the direct interaction network using IPA. Upregulated genes (EDN1,
INHBA,TGFβ1,TGFβ2, RUNX1, LHX8, SNAI1, PDGFC, and PIGA) were
highlighted with orange and downregulated gene (SMAD3) was
highlighted with green.TGFβR1 was upregulated withTGFβ1 treatment
and downregulated withTGFβ2 treatment, thus highlighted with cyan.
Fx, cellular function; CP , canonical pathway.
TGFβ3,butlessthanTGFβ1.This,combinedwiththeobservation
thatTGFβ2isexpressedprimarilyinthemesenchymeregion(Fitz-
patrick et al.,1990),indicates its important role within the palatal
mesenchyme. Since TGFβ1 is expressed in both the palatal mes-
enchyme and epithelium, it has been proposed to facilitate cross-
talkbetweenthecelltypesduringpalatedevelopment(Fitzpatrick
etal.,1990).Therefore,itisexpectedthatTGFβ1wouldaffectmore
genes compared to TGFβ2 and TGFβ3. Surprisingly, the number
of genes signiﬁcantly altered by TGFβ3 was minimal, which may
suggest that TGFβ3 is less involved in the regulation of cellular
functions of palatal mesenchyme. However,this does not rule out
its major role within the MEE during palatogenesis. Meanwhile,
the high number of differentially up- and downregulated genes
within the intersection regions, particularly between TGFβ1 and
TGFβ2, suggests that TGFβ isoforms may simultaneously coordi-
nate the development of the palatal mesenchyme. We identiﬁed a
strongcorrelationof geneexpressionpatternsbetweenmicroarray
andqPCRdataintermsofup-anddownregulationofsigniﬁcantly
differentially expressed genes, but not relative level of expression.
Expression proﬁles of all 27 genes tested were found to be in
agreement between the two methods (Figure3),further conﬁrm-
ingthereliabilityof thehybridization-basedgeneexpressionassay.
Visualization of the vast amount of microarray data is an
essential step for the accurate interpretation of the acquired data.
Unsupervised hierarchical clustering presented as a heatmap and
dendrogram is a common approach for detecting coexpressed
groups of genes (Eisen et al.,1998). The heatmaps of differentially
expressed genes according to cellular biofunctions allowed us to
detect progressively and distinctly up- or downregulated genes.
The heatmaps also showed us that most of the genes altered sig-
niﬁcantlyinresponsetoTGFβ1andTGFβ2followedaverysimilar
pattern, unlike TGFβ3, which effected gene expression to a lower
extent in the HEPM cells (Figure 4).
THE MOST SIGNIFICANTLY UPREGULATED TRANSCRIPTS
There were 27 genes grouped as the most signiﬁcantly altered,
in which 13 of them were upregulated and 14 of them were
downregulated, in response to TGFβ stimulation (Table 2).
Although,not all of them presented a direct/indirect relation with
TGFβmoleculeaccordingtoIPA(Figure2),here,weprovidetheir
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FIGURE 7 |TGFβ signaling pathway overlaid with differentially expressed
genes. Cellular localization of differentially expressed genes active in
canonicalTGFβ pathway was illustrated using the IPA Path Designer. Genes in
Table 1 were uploaded to IPA as a dataset and analyzed using default settings.
Acquired networks were overlaid withTGFβ canonical pathway.The
overlapping genes are:TGFβ1,TGFβ2, INHBA (activins/inhibins), BMPR2,
SMAD7, SMURF1, SMAD 1/5/8, SMAD2/3, VDR, and PAI-1. Green color
represents downregulated expression, whereas red color represents
upregulated expression of genes. Color intensity reﬂects the level of
expression.Types of molecules are annotated in the legend in the box.
potential interaction with TGFβ and/or cleft palate based on most
recent literature review. Further detailed discussion of all 27 genes
can be found at Table A3 in Appendix.
In our study, AMIGO2 was the most signiﬁcantly upregulated
gene in TGFβ-treated HEPM cells. In a recent study by Gimelli
etal.(2011),ithasbeenshownthatapatientexhibitingcleftpalate,
mental retardation, and high myopia carries a de novo 12q13.11
microdeletion, which harbors 16 genes including AMIGO2. This
genetic analysis shows that AMIGO2 might have a role in one of
the symptoms mentioned above, including cleft palate.
Several studies showed that TGFβ1 regulates expression of
NOX4 in airway smooth muscle cells (Sturrock et al., 2006), car-
diacﬁbroblasts(Cucoranuetal.,2005),renalepithelialcells(Rhyu
et al., 2005), and keratinocytes (Davies et al., 2005). Upregulated
expression of Nox4 in palatal mesenchyme may assign a crucial
role to Nox4 during palate development under TGFβ regulation.
In our study, TGFβ treatment induced high-level expression
of TNFAIP6 and HAPLN1, both hyaluronan-related genes, in
the palatal mesenchyme, which may suggest that TGFβ mediates
hyaluronanproductionrequiredforpalatalshelfreorientationand
extension.
Expression levels of two Wnt-mediated genes, DAPPER1
(DACT1) and ANKRD1 (CARP) genes were upregulated in
response to TGFβ treatment. During embryonic development,
TGFβ and Wnt signaling exhibit synergistic effects (Letamen-
dia et al., 2001; Lei et al., 2004; Deng et al., 2008; Owens et al.,
2008; Micalizzi et al., 2010), and both DAPPER1 and ANKRD1
are involved in both of these pathways (Waxman et al., 2004;
Labbe et al.,2007; Su et al.,2007). Based on our detection of their
upregulated expression, we suggest that these genes may serve as
mediators of cross-talk between TGFβ and Wnt signaling during
palate development.
PMEPA1 is a TGFβ-induced transmembrane protein (Brun-
schwig et al., 2003) and was upregulated following TGFβ stimu-
lation. Although PMEPA1’s distinct role in development has not
been studied yet, its upregulated expression and association with
TGFβ make it an important candidate for the regulation of palatal
mesenchyme development.
EDN1, which is a candidate for non-syndromic orofacial cleft
disease based on evidence from linkage analysis and mouse model
knockouts(Kuriharaetal.,1994;Satoetal.,2008),wasalsoupreg-
ulated. Thus, we suggest that TGFβ isoforms may regulate the
expression of EDN1 and/or its transcriptional activators, which
requires further elucidation.
ThevitaminDreceptor(VDR),whichencodesthenuclearhor-
monereceptorforvitaminD3,wasalsohighlystimulatedbyTGFβ
treatment (Table 2). The TGFβ and vitamin D signaling path-
ways are involved in synergistic and antagonistic cross-talk, in a
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Table 3 | List of differentially expressed genes targetingTGFβ signaling
molecules.
Gene name TGFβ1 FC TGFβ2 FC TargetTGFβ molecule
BMPR2 1.42 1.38 SMURF1
CTGF 2.00 1.95 SMAD7
SMAD3
TGFβ1
TGFβ2
ITGB3 5.19 4.42 PAI1
SERPINE1 (PAI1) 1.83 1.96 SMAD7
PAI1
SMAD3
TGFBR1
TGFβ1
TGFβ2
SMAD1 1.48 NS SMURF1
BMPR2
TGFBR1
SMAD3 −3.24 −2.51 SMAD7
SMAD3
BMPR2
TGFBR1
TGFβ1
TGFβ2
SMAD7 4.17 4.04 SMAD7
SMURF1
INHBA
TGFβ1
TGFβ2
TGFB1 1.91 1.59 PAI1
SMAD3
TGFBR1 1.49 NS SMAD7
SMURF1
TGFBR1
NS, non-signiﬁcant expression detected by dChip; FC, fold-change from micro-
array analysis.
tissue-speciﬁc manner,facilitated through the binding of SMAD3
andVDR to their associated binding sites (Yanagisawa et al.,1999;
Subramaniam et al.,2001). Given its role as a mediator in normal
physiologyanditshigh-levelexpressioninresponsetoTGFβtreat-
ment,weproposethatVDRmediatesthecommunicationbetween
TGFβ and Vitamin D during palatogenesis. Further veriﬁcation
of this intermediation may also shed light on the importance of
Vitamin D as an environmental etiological factor of cleft palate.
Ithasbeenproposedthatpalatalshelfelevationcanbedrivenby
thegrowth(andmovement)of thefacialskeletalmusclesinducing
mechanotransductionpathways,whichinturnregulatecytoskele-
ton remodeling, cell proliferation, and tissue differentiation
(Innes,1978;Farge,2011).MSC(musculin),alsoknownasMyoR,
is a basic helix-loop-helix (bHLH)-type transcriptional regulator
of myogenesis; and we detected its expression as upregulated with
TGFβ treatment. Considering its capability of binding to the E-
box element and muscular movement during palatogenesis, we
postulatethatMSCandTGFβisoformscanmodulateeachother’s
expression in a feedback loop during palate formation.
I nas t u d yc o n d u c t e db yVogel et al. (2010), it is documented
that TGFβ1 regulates expression of NEDD9,a scaffolding protein,
to promote the differentiation of hippocampal and cortical cells
intoneurons.SimilartoTGFβisoforms,NEDD9isassociatedwith
diverse biological processes including cell attachment, migration,
andinvasion,aswellasapoptosisandcellcycleregulation.Consid-
ering its high-level expression observed in palatal mesenchyme, it
is conceivable that NEDD9 may mediate crucial processes during
palatogenesis in a close relation with TGFβ.
THE MOST SIGNIFICANTLY DOWNREGULATED TRANSCRIPTS
GDF5 is a member of the TGFβ superfamilyandisinvolvedincell
adhesion and differentiation of mesenchymal cells to chondro-
cytes (Takahara et al., 2004). Considering its reduced expression
in the embryonic palatal mesenchyme, we hypothesize that TGFβ
signaling inhibits GDF5 expression to block the mesenchymal
differentiation into ossiﬁcation centers, in favor of mesenchymal
proliferation during palatal growth.
Based on the network analysis, which is developed using the
IPA (data not shown), SECTM1 has an indirect relationship with
SMAD3 and HGF,both of which were downregulated upon TGFβ
treatment.Although,toourknowledge,thereisnostudyavailable
focusing on the role of SECTM1 during development, its down-
regulated expression in response to TGFβ may be associated with
SMAD3’s decreased expression, which may suggest that SECTM1
is regulated under TGFβ signaling.
Human NPTX1 mRNA is exclusively localized to the nervous
system during development (Omeis et al., 1996), and promotes
apoptosis within the developing cortical neurons in culture (Abad
et al., 2006). Although its function during craniofacial devel-
opment has not been described yet, its signiﬁcant downregula-
tion in TGFβ-treated HEPM can be explained by requirement
for inhibition of cell death during the morphogenesis of palatal
mesenchyme.
Another apoptosis-related gene, OAS1 (Hale et al., 2008), was
also downregulated with TGFβ treatment. Since the palatal mes-
enchyme is constantly proliferating and growing during the initial
stages of palatogenesis, reduced expression of OAS1, resulting
in inhibition of apoptosis, is a required step for the continuous
development of the palate.
SMAD3 is one of the intracellular mediators that transduce
signals from TGFβ receptors. It has been demonstrated that
SMAD2/3 is involved in growth inhibition of mouse embryonic
palate mesenchymal cells (MEMP) induced by all-trans retinoic
acid(Wangetal.,2009).Ourstudyshowingdownregulatedexpres-
sion of SMAD3 in response to TGFβ may suggest that SMAD3 is
required to be inhibited during palatal development to maintain
consistent growth of palatal shelves until attachment.
TheVSIG1 gene encodes a member of the junctional adhesion
molecule (JAM) family. Since the mesenchymal cells of the palate
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do not express adherens junction proteins (Nawshad et al., 2004),
reduced expression of VSIG1 by TGFβ suggests that regulation of
VSIG1isrequiredforintegrityof mesenchymalcellsof developing
palate.
In epithelial cells, TGFBR3 inhibits TGFβ signaling by pre-
venting the formation of the TGFBR1–TGFBR2 complex,thereby
functioningasapotentTGFβneutralizingagent(Vilchis-Landeros
etal.,2001;Eickelbergetal.,2002).Forthemaintenanceof proper
communicationofTGFβsignalingwithinthepalatalmesenchyme,
itisessentialthatexpressionlevelsof TGFBR3areminimized;thus
both TGFβ1 and TGFβ2 treatment facilitated downregulation of
TGFBR3.
HGF has been demonstrated to cell growth (Boccaccio et al.,
1998), cell motility (Hajjar and Nachman, 1996), and morpho-
genesis (Suniletal.,2002)byactivatingatyrosinekinasesignaling
cascade (Porter and Vaillancourt, 1998). In several types of cells,
it has been shown that TGFβ, even at low concentrations, signiﬁ-
cantly reduces HGF production [87;88]. Based on downregulated
expressionofHGF,wehypothesizethatthereisanegativefeedback
betweenTGFβandHGFfortheproperdevelopmentof thepalate.
CONCLUSION
Inconclusion,wehavedeterminedthatmorethan2%(n =566)of
thehumangenesweredifferentiallyexpressedinpalatalmesenchy-
mal cells in response to treatment with TGFβ isoforms.According
to GO annotation clustering, 234 of these altered genes (41%)
were associated with cellular biofunctions. Nevertheless, only 11
of these transcripts were implicated in craniofacial deformities,
which suggest that other etiological factors are correspondingly
involved in the development of palatal constituents. Our overall
results suggest that both TGFβ1 and TGFβ2 isoforms regulate the
expressionof genesthatgoverncellularbiofunctionsof thepalatal
mesenchyme;andthisregulationiscrucialfornormalpalatogene-
sis.Furtherelucidationof thesigniﬁcantlyup-anddownregulated
genes at the protein level will enhance our understanding of the
mechanismscontrollingpalatedevelopment;therebypavetheway
for prevention of cleft palate during development.
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APPENDIX
TableA1 | Primers for q-RTPCR.
Gene name Entrez ID Fw primer Rv primer
AMIGO2 NM_001143668.1 CAACATCACCAGCATTTCCAC TCACCGTCTTCAGCTTATTGG
NOX4 NM_016931 TCACAGAAGGTTCCAAGCAG ACTGAGAAGTTGAGGGCATTC
TNFAIP6 NM_007115.3 AATACAAGCTCACCTACGCAG GGTATCCAACTCTGCCCTTAG
DACT1 NM_016651.5 TTGGAGGAGAACATCTTGCTG GTCTTTTCTACATCCAGTCTCAGG
ANKRD1 NM_014391.2 GGTGAGACTGAACCGCTATAAG GGCTGTCGAATATTGCTTTGG
PMEPA1 NM_020182 GCAAACGCTCTTTGTTCCAG ACCATCACCATCATCACCAC
MSC NM_005098.3 CGCTATGAGAACGGCTACG CCCATCAAGTGAGTTCCAGTC
EDN1 NM_001955 CTTCGTTTTCCTTTGGGTTCAG GCTCAGCGCCTAAGACTG
VDR NM_000376.2 CACTATTCACCTGCCCCTTC CTTCCTCTGCACTTCCTCATC
ITGB3 NM_000212.2 CAAGTGTGAATGTGGCAGC TTTTCGTCATGTAGGGCTCC
KCNH1 NM_172362.2 GCCTTCTCCCATTCCTTCTC CCTCATTCTTTCGTTTCATGCG
HAPLN1 NM_001884.3 AGTGTGAGGTGATTGAAGGATTAG CTGCGCCTCGTGAAAATTG
NEDD9 NM_006403.3 TGTAGGAAAACGGCTCAACC CCCTGTGTTCTGCTCTATGAC
GDF5 NM_000557 .2 ACAGAAAGGGAGGCAACAG CTTCTCCAGGGCACTAATGTC
SECTM1 NM_003004.2 GACACCAGAGAAATAACAGACAAG GTACCAGGCGAACATGACC
NPTX1 NM_002522.3 GCCCTATCACCCCATCAAG TTGCGGTCCCAGATGTTG
SMAD3 NM_005902 TCCATCCCCGAAAACACTAAC CATCTTCACTCAGGTAGCCAG
OAS1 NM_016816 CATCTGTGGGTTCCTGAAGG GAGAGGACTGAGGAAGACAAC
TBC1D8 NM_001102426 CCCAGGTTTATTCTCCCATAGC AGCCTTTACCTTCCCTTTGAC
TRERF1 NM_033502.2 GTGATGGTTGCTCTGGAAATG TCTTTGCTGTAAGTGGCTAGTG
VSIG1 NM_182607 GCTCTCAACTAACCTCCACAC AGATCCAACAGTCACGTTCAC
TGFBR3 NM_003243.4 CGGAAACATCACCTTCAACATG CCCAGTTCTTGTTCAGCCTTAG
CA12 NM_001218 CAGGTCCAGAAGTTCGATGAG CAATACAGATGCCAAGAATGCC
ARHGAP28 NM_001010000 AGTAAAAGGACGAGACAATGGG ATTCCTTCAGATTCCAGACCTG
HGF NM_000601.4 GCTATACTCTTGACCCTCACAC GTAGCCTTCTCCTTGACCTTG
NR4A2 NM_006186 CTGGCTGTTGGGATGGTC TGTGGGCTCTTCGGTTTC
IFIT2 NM_001547 .4 GAAGATTTCTGAAGAGTGCAGC CCTCCATCAAGTTCCAGGTG
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TableA2 | Genes susceptible for cleft palate.
Abca4 Fst Mthfr Tbx1
Acvr2* Gabrb3 Myf5 Tbx22
Acvr2a Gad1* Myod1* Tbx3*
Apaf1* Gad2* Nat2 Tcof1
Bmp Gas1 Ofd1 Tgfα
Bnc2* Gli Pax9 Tgfβ1*
Cask* Gli3 Pdgfc* Tgfβ2*
Cdkn1c* Gpc3 Pdgfr-α* Tgfβ3
Col11a1 Hic1* Pds5* Tgfβr1*
Col11a2 Hoxa2 Pds5b* Tgif1
Col2a1 Hspg2 Piga* Tgif2
Crk* Hyal1 Pitx1 Tp63
Cspg Inhba* Pitx2 Tshz1*
Dhcr7* Insig1* Prrx1* Vax1*
Dlx1* Insig2* Ptprf* Vcan*
Dlx5* Integrin* Ptprs* Viaat*
Dtdst Irf-6 Pvrl1 Vlk*
Edn1* Itgav* Ryk Wnt
Edna* Itgb6* Satb2 Wnt9b*
Egf Itgb8* Shh Zeb1
Egfr Jag2 Shox2*
Esr1 Lgr5* Sim2*
Fgf Lhx8* Six3
Fgf-10* Mafb SMAD2
Fgfr Meox1* SMAD3
Fgfr-2* Mid1 SMAD4
Folr1* Mmp Snail 1
Foxc2 Mn1* Snail 2*
Foxe1 Mnt* Snail 3*
Foxf2 Msx1 Sox9
*Putative genes, which may cause cleft palate in human.
Differentially expressed putative cleft palate genes in response to TGFβ1 and
TGFβ2.
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TableA3 | Details of the most signiﬁcantly altered genes within the palatal mesenchyme.
Gene Entrez Gene Name Function in the cell
Most
Upregulated
AMIGO2 Adhesion molecule with Ig-like domain 2 Cell–cell adhesion, apoptosis, adhesion, survival
NOX4 NADPH oxidase 4 Proliferation, expression, apoptosis, morphogenesis, aging, growth, cell death,
NADPH oxidase activity
TNFAIP6 Tumornecrosisfactor,alpha-inducedfac-
tor 6
Signaling, adhesion, expansion, assembly
DACT1 Dapper homolog 1 Multicellular organismal development; Wnt receptor signaling pathway
ANKRD1 Ankyrin repeat domain 1 Apoptosis, colony formation
PMEPA1 Prostate transmembrane protein, andro-
gen induced 1
Apoptosis, growth; androgen receptor signaling pathway
MSC Musculin Myogenesis; skeletal muscle development; palate development; regulation of
transcription
EDN1 Endothelin 1 Proliferation, migration, growth, apoptosis, gene expression, stimulation, pH,
activation, invasion
VDR Vitamin D (1,25-dihydroxyvitamin D3)
receptor
Apoptosis, development, proliferation, homeostasis, differentiation, osteoclas-
togenesis, transcription
KCNH1 Potassium voltage-gated channel mem-
ber 1
Growth, proliferation, fusion, hyperexcitation
HAPLN1 Hyaluronanandproteoglycanlinkprotein
1
Cell adhesion; hyaluronic acid binding
NEDD9 Neural precursor cell expressed, devel-
opmentally downregulated 9
Migration, invasion, proliferation, apoptosis, quantity, cell division, cell spread-
ing, survival, activation
ITGB3 Integrin, beta 3 Adhesion, migration, aggregation, cell spreading, proliferation, activation, apop-
tosis, invasion, angiogenesis; negative regulation of cell death
Most Downreg-
ulated
GDF5 Growth differentiation factor 5 Differentiation, apoptosis, signaling, adhesion, proliferation, migration; cell–cell
signaling; limb morphogenesis;TGFβR signaling pathway
SECTM1 Secreted and transmembrane 1 Immune response; mesoderm development; positive regulation of IKB
kinase/NFKB cascade; signal transduction
NPTX1 Neuronal pentraxin I Synaptic transmission, cell death, outgrowth, apoptosis, cell–cell contact, loss,
chemotaxis; central nervous system development
SMAD3 SMAD family member 3 Growth, proliferation, apoptosis, differentiation, chemotaxis; cell–cell junction
organization; cell cycle arrest; developmental growth
OAS1 2 –5 -oligoadenylate synthetase 1 Apoptosis; cellular response to interferon-alpha; cytokine-mediated signaling
pathway; defense response to virus
TBC1D8 TBC1 domain family, member 8 Proliferation, formation; blood circulation; cell proliferation; regulation of Rab
GTPase activity
TRERF1 Transcriptional regulating factor 1 Replication; homeostatic process; multicellular organismal development; reg-
ulation of transcription
VSIG1 V-set and immunoglobulin domain con-
taining 1
Member of the junctional adhesion molecule (JAM) family
TGFBR3 Transforming growth factor, beta recep-
tor III
Growth, apoptosis, proliferation, invasiveness, motility, movement, differentia-
tion; epithelial to mesenchymal transition;TGFβ receptor signaling
CA12 Carbonic anhydrase XII Growth; one-carbon metabolic process; type I membrane protein
ARHGAP28 Rho GTPase activating protein 28 Positive regulation of small GTPase activity; signal transduction
HGF Hepatocyte growth factor Migration, scattering, proliferation, apoptosis, invasion, growth, expression,
motility, branching, morphogenesis
NR4A2 Nuclear receptor subfamily 4, group A,
member 2
Differentiation, maturation, degeneration, quantity, migration, growth, survival;
negative regulation of apoptosis
IFIT2 Interferon-induced protein with tetratri-
copeptide repeats 2
Cellular response to interferon-alpha; cytokine-mediated signaling pathway;
negative regulation of protein binding; type I interferon-mediated signaling
pathway
(Continued)
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TableA3 | Continued
Gene Entrez Gene Name Function in the cell
Cleft
Palate-related
EDN1 Endothelin 1 Proliferation, migration, growth, apoptosis, gene expression, stimulation, pH,
activation, invasion
INHBA Inhibin, beta A Apoptosis,growth,differentiation,cellcycleprogression,proliferation,quantity,
induction, cell death
LHX8 LIM homeobox 8 Development,maturation,differentiation,quantity;femalegonaddevelopment;
forebrain neuron development
PDGFC Platelet derived growth factor C Proliferation, migration, formation, mitogenesis, growth, chemotaxis, motility;
activation of transmembrane receptor protein tyrosine kinase activity
PIGA Phosphatidylinositol glycan anchor
biosynthesis, class A
Morphogenesis, colony formation, hemolysis, quantity; biosynthetic process;
cellular protein metabolic process
RUNX1 Runt-related transcription factor 1 Differentiation, apoptosis, growth, proliferation, transcription, activation, sur-
vival; skeletal system development; DNA-dependent transcription
SMAD3 SMAD family member 3 Growth, proliferation, apoptosis, differentiation, chemotaxis; cell–cell junction
organization; cell cycle arrest; developmental growth
SNAI1 Snail homolog 1 Apoptosis, epithelial–mesenchymal transition, migration, cell cycle progres-
sion, binding, transcription, dissemination; osteoblast differentiation; palate
development
TGFβ1 Transforming growth factor, beta 1 Multifunctional peptide that regulates proliferation, differentiation, adhesion,
migration
TGFβ2 Transforming growth factor, beta 2 Proliferation, apoptosis, growth, differentiation, cell cycle progression, cell
death, migration, cytostasis, development; angiogenesis; axon guidance; blood
coagulation
TGFβR1 Transforming growth factor, beta recep-
tor 1
Apoptosis, differentiation, proliferation, growth, migration, motility, cell cycle
progression, phosphorylation; signal transduction; skeletal system develop-
ment
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TableA4 |The full list of genes regulated by differentially expressed
TGFβ signaling molecules and their level of altered expression.
Molecule Gene TGFβ1 TGFβ2
SMAD7 Alpha1 NS NS
CDKN1A NS NS
CDKN2B NS NS
COL1A1 NS NS
COL3A1 NS NS
Collagen NS NS
CTGF 2.00 1.95
MAPK NS NS
P38 NS NS
SERPINE1 1.83 1.96
SMAD2 NS NS
Smad2/3 NS NS
SMAD3 −3.24 −2.51
SMAD7 4.17 4.04
TGFBR1 1.49 NS
TGFBR2 NS NS
SMURF1 BMPR2 1.42 1.38
MAP3K2 NS NS
RHOA NS NS
RUNX2 NS NS
SMAD1 1.48 NS
SMAD1/5/8 NS NS
SMAD4 NS NS
SMAD5 NS NS
SMAD7 4.17 4.04
TGFBR1 1.49 NS
TRAF1 NS NS
TRAF4 NS NS
BMPR2 ID1 NS NS
ID2 NS NS
MAP3K7 NS NS
MAPK NS NS
P38 NS NS
PKA NS NS
Ras NS NS
SHC1 NS NS
SMAD1 1.48 NS
Smad1/5/8 NS NS
SMAD3 −3.24 −2.51
SMAD5 NS NS
TGFBR1 CDKN1A NS NS
Erk1/2 NS NS
MAP3K7 NS NS
Ras NS NS
SERPINE1 1.83 1.96
SMAD1 1.48 NS
SMAD2 NS NS
SMAD3 −3.24 −2.51
SMAD4 NS NS
Tab1–Tak1 NS NS
TGFBR1 1.49 NS
Gene TGFβ1 TGFβ2
Molecule Gene TGFβ1 TGFβ2
SERPINE1 (PAI1) F2 NS NS
FLT1 NS NS
FN1 NS NS
ITGAV NS NS
ITGB3 5.19 4.42
Laminin NS NS
LRP1 NS NS
PLAT NS NS
PLAU NS NS
PLAUR NS NS
PLG NS NS
SERPINE1 1.83 1.96
TGFB1 1.91 1.59
VTN NS NS
VDR BGLAP NS NS
Ca2+ NS NS
CYP24A1 NS NS
CYP27B1 NS NS
FGF23 NS NS
IL2 NS NS
PTH NS NS
REN NS NS
Renin NS NS
RXRA NS NS
S100G NS NS
SLC34A1 NS NS
TGFβ1 ACTA2 NS NS
CDH1 NS NS
CDKN1A NS NS
CDKN2B NS NS
COL1A1 NS NS
COL1A2 NS NS
CTGF 2.00 1.95
FN1 NS NS
FOXP3 NS NS
SERPINE1 1.83 1.96
SMAD2 NS NS
SMAD3 −3.24 −2.51
SMAD4 NS NS
SMAD7 4.17 4.04
Gene TGFβ1 TGFβ2
SMAD3 Alp NS NS
CDKN1A NS NS
CDKN2B NS NS
COL1A2 NS NS
CTGF 2.00 1.95
FSHB NS NS
IFNG NS NS
IL2 NS NS
NOS2 NS NS
SERPINE1 1.83 1.96
SMAD3 −3.24 −2.51
(Continued)
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TableA4 | Continued
Molecule Gene TGFβ1 TGFβ2
TBX21 NS NS
TGFB1 1.91 1.59
INHBA ACVR1B NS NS
ACVR2B NS NS
BAX NS NS
CCND2 NS NS
CDKN1A NS NS
CDKN2B NS NS
CGA NS NS
CYP11A1 NS NS
FSH NS NS
FSHB NS NS
FSHR NS NS
FST NS NS
GNRHR NS NS
INSULIN NS NS
SMAD7 NS NS
TGFβ2 CDKN1A NS NS
CDKN2B NS NS
COL1A1 NS NS
COL1A2 NS NS
CTGF 2.00 1.95
FN1 NS NS
FOS NS NS
FOXP3 NS NS
SERPINE1 1.83 1.96
SMAD2 NS NS
SMAD3 -3.24 -2.51
SMAD4 NS NS
SMAD7 4.17 4.04
TNF NS NS
NS, non-signiﬁcant expression detected by dChip.
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